Clinical-stage cancer immunotherapy firm Compugen's Q3 net loss widens
Compugen reported a Q3 revenue of $1.9 million, exceeding analyst expectations but down from the previous year. The net loss widened to $6.98 million compared to a profit last year. The company expects its cash reserves to sustain operations until Q3 2027 and is advancing its GS-0321 trial licensed to Gilead. Analysts maintain a strong buy rating, with a median 12-month price target of $4.00, reflecting a potential upside of 59.5% from its recent closing price of $1.62.
)
Overview
- Compugen Q3 revenue of $1.9 mln beats analyst expectations but declines from prior year
- Net loss for Q3 was $6.98 mln, compared to a net profit last year
Outlook
- Company expects cash reserves to fund operations into Q3 2027
- Company advancing GS-0321 trial, licensed to Gilead
Result Drivers
- FINANCIAL POSITION - Solid financial position with cash runway expected to fund operations into Q3 2027
Key Details
Metric Beat/Mis Actual Consensu
s s
Estimate
Q3 Beat $1.89 $1.47
Revenue mln mln (3
Analysts
)
Q3 EPS -$0.07
Q3 Net -$6.98
Income mln
Q3 Gross $241,000
Profit
Q3 $8.13
Operatin mln
g
Expenses
Q3 -$7.89
Operatin mln
g Income
Analyst Coverage
- The current average analyst rating on the shares is “strong buy” and the breakdown of recommendations is 4 “strong buy” or “buy”, no “hold” and no “sell” or “strong sell”
- The average consensus recommendation for the biotechnology & medical research peer group is “buy.”
- Wall Street’s median 12-month price target for Compugen Ltd is $4.00, about 59.5% above its November 7 closing price of $1.62
Press Release: For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact . (This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
